

Freedom of Information Act 2000 – Request Reference FoI/24/155
Biologic and Targeted Medications

Q1. How many patients were treated in February 2024 (or latest available month) by the Dermatology department with the following drugs:

Abrocitinib (Cibinqo) – 2
Baricitinib (Olumiant) – 6
Dupilumab (Dupixent) – 45
Lebrikizumab (Ebglyss) – 0
Omalizumab (Xolair) – 9
Tralokinumab (Adtralza) – 2
Upadacitinib (Rinvoq) – 9

Q2. How many patients were treated in February 2024 (or latest available month) by the Respiratory Medicine departments with the following drugs:

Benralizumab (Fasenra) – 28
Dupilumab (Dupixent) – 25
Mepolizumab (Nucala) – 17
Omalizumab (Xolair) – 13
Reslizumab (Cinqaero) – 0
Tezepelumab (Tezspire) – 49